Aduro is collaborating with Novartis on the research, development, and commercialization of novel cancer immunotherapy products targeting the STING pathway. ADU-S100, the first therapeutic in clinical development specifically targeting STING, is being evaluated in a clinical trial for the treatment of cutaneously-accessible tumors, such as breast, head-and-neck, and renal cell cancers as well as lymphoma and melanoma.
Aduro is collaborating with Merck (known as MSD outside the United States and Canada) under a worldwide license agreement for the development and commercialization of CD27 antibody agonists. Merck has selected an anti-CD27 antibody identified through Aduro’s B-select monoclonal antibody technology to advance into the clinic.
Aduro is collaborating with Janssen Biotech, Inc. on the development of LADD®-based product candidates to treat prostate (ADU-741/JNJ-64041809) and lung (ADU-214/JNJ-64041757) cancers. Both programs are in ongoing clinical trials.
Aduro is collaborating with researchers at Johns Hopkins to develop next-generation therapeutic approaches by combining GVAX, LADD and cyclic dinucleotides in multiple cancer indications.
Aduro is partnering with The University of California (UC) Berkeley on the Immunotherapeutics and Vaccine Research Initiative (IVRI) to develop new immunotherapies for treating and preventing cancer, infectious disease, and autoimmune disease. The initiative combines UC Berkeley’s research capabilities with the company’s expertise in immunotherapy discovery and development.